Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HRS-5346
MK-7262 · 1 trial · 1 indication
Blood samples will be collected at baseline and at Week 8 to assess the mean percent change from baseline in Lp(a).
Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants will receive MK-7262 placebo + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment. |
| enlicitide monotherapy | ACTIVE_COMPARATOR | Participants will receive enlicitide + MK-7262 placebo orally once daily (QD) for up to approximately 12 weeks of treatment. |
| MK-7262 monotherapy | EXPERIMENTAL | Participants will receive MK-7262 + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment. |
| MK-7262 + enlicitide | EXPERIMENTAL | Participants will receive MK-7262 + enlicitide orally once daily (QD) for up to approximately 12 weeks of treatment. |
| Name | Type | Description |
|---|---|---|
| MK-7262 | DRUG | Oral Coated Tablet |
| Enlicitide | DRUG | Oral Coated Tablet |
| Placebo for MK-7262 | DRUG | Oral Coated Tablet |
| Placebo for enlicitide | DRUG | Oral Coated Tablet |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has Lp(a) ≥ 150 nmol/L * Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study Exclusion Crite...
MK-7262 is an investigational small molecule being developed by Merck & Company, Inc. (ticker MRK) for high lipoprotein(a). It is currently in Phase 2 clinical development and has not been approved by the FDA. It is being studied in adults with elevated lipoprotein(a), a condition associated with cardiovascular risk.
MK-7262 is being developed for the treatment of high lipoprotein(a), also written as elevated Lp(a). Lipoprotein(a) is a cholesterol-carrying particle in the blood, and elevated levels are the target condition in the ongoing clinical program. The drug is investigational and is not yet approved for any use.
MK-7262 is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the clinical program evaluating the drug in participants with high lipoprotein(a). No partnership or licensing details for MK-7262 have been disclosed.
MK-7262 is in Phase 2 clinical development. The program includes one trial, which is currently recruiting participants. Because the drug remains investigational, it has not received FDA approval. The Phase 2 study is titled MK-7262-004 and is evaluating MK-7262 and enlicitide in people with high lipoprotein(a).
MK-7262 is being studied in one Phase 2 trial, NCT07614984, titled A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004). The trial is recruiting and plans to enroll 750 participants aged 18 years and older across the United States, Canada, Colombia, Denmark, Germany, Japan, the Netherlands, Spain, and Switzerland.
The MK-7262 Phase 2 trial, NCT07614984, is a randomized, double-blind, placebo-controlled study. It plans to enroll 750 adults with high lipoprotein(a) and is currently recruiting across nine countries. Participants are 18 years of age or older, and the study does not enroll healthy volunteers.